rTSβ as a novel 5-fluorouracil resistance marker of colorectal cancer: A preliminary study

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 2, 2010, Pages 107-111

  Lin, Yu Li ^a,b   Chow, Kuan Chih ^b  

^a CHENG CHING GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Immunohistochemistry; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE BETA; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; HOSPITAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR BIOPSY; COLORECTAL TUMOR; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; PHYSIOLOGY; TAIWAN; TUMOR CELL LINE;

BIOLOGICAL MARKERS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOLOGICAL TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; TAIWAN; THYMIDYLATE SYNTHASE;

EID: 77949518385     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Annual reports of the Department of Health, the Executive Yuan, Republic of China 2004.
2. Taiwan Cancer Organization Group, Cancer practices guideline of the National Health Research Institutes, Republic of China 1998. (http://www.nhri.org.tw) Accessed on 23 May 2009.
3. Schmoll HI, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999;26:589-605.
4. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
5. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
6. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
7. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62.
8. Montfort WR, Weichsel A. Thymidylate synthase: structure, inhibition, and strained conformations during catalysis. Pharmacol Ther 1997;76:29-43.
9. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. Thymidylate synthase level as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 1999;19:5621-6.
10. Peter GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Review article: induction of thymidylate synthase as a 5-fluorourcil resistant mechanism. Biochim Biophys Acta 2002;1587:194-205.
11. Peter GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995;31:1299-305.
12. Dolnick R, Wu Q, Angelino NJ, Stephanie LV, Chow KC, Sufrin JR, et al. Enhancement of 5-Fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells. Cancer Res 2002;65:5917-24.
13. Dolnick BJ. Cloning and characterization of a naturally occurring antisense RNA to human thymidylate synthase mRNA. Nucleic Acids Res 1993;21:1747-52.
14. Dolnick BJ, Black A. Alternate splicing of the rTS gene product and its overexpress in a 5-fluorourcil-resistant cell line. Cancer Res 1996;56:3207-10.
15. Dolnick BJ, Black AR, Winkler PM, Schindler K, Hsueh CT. rTS gene expression is associated with altered cell sensitivity to thymidylate synthase inhibitors. Adv Enzyme Regul 1996;36:165-80.
16. Dolnick BJ, Angelino NJ, Dolnick R, Sufrin JR. A novel function for the rTS gene. Cancer Biol Ther 2003;2:364-9.
17. Chiou CF, Chow KC, Lin FM, Lin CK, Liu SM, Chen KY. Expression of DNA topoisomerase II and multidrug resistance p-glycoprotein in acute leukemia - an immunohistochemical study. Chin Med J (Taipei) 1997;60:184-90.
18. Chow KC, Ross WE. Topoisomerase specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 1987;7:3119-23.
19. Hsu NY, Ho HC, Chow KC, Lin TY, Shih CS, Wang LS, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001;61:2727-31.
20. Yamaue H, Tanimura H, Nakamori M, Noguchi K, Iwahashi M, Tani M, et al. Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MT assay. Dis Colon Rectum 1996;39:416-22.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am Stat Assoc 1958;53:457-81.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996;50:163-70.
23. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
24. Black AR, Dolnick BJ. Expression of rTS correlates with altered growth regulation of thymidylate synthase. Cancer Res 1996;56:700-5.
25. Chow KC, Chow SL, Chi KH, Chen KY. The application of leucovorin in the chemotherapy of cancers. Therapeut Radiol Oncol 1995;2:79-85.
26. Babbitt P, Mrachko G, Hasson M, Huisman GW, Kolter R, Ringe D, et al. A functionally diverse enzyme superfamily that abstracts the alpha protons of carbocylic acids. Science 1995;267:1159-61.
27. Huisman G, Kolter R. Sensing starvation: a homoserine lactone-dependent signaling pathway in Escherichia coli. Science 1994;265:537-9.
28. Pagliaro L, Taylor DL. 2-Deoxyglucose and cytochalasin D modulate aldolase mobility in living 3T3 cells. J Cell Biol 1992;118:859-63.
29. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 2002;115:3403-14.